论文部分内容阅读
目的分析布地奈德联合孟鲁司特钠治疗支气管哮喘的临床效果及安全性。方法将96例支气管哮喘患者随机分为对照组和观察组各48例,对照组给予布地奈德气雾剂喷雾吸入,100μg/次,2次/d;观察组加用孟鲁斯特纳片口服,10mg/次,1次/d。14d为1个疗程,连续治疗2个疗程,共28d。结果治疗后,观察组患者气道通气功能(FEV1、FVC、FEV1/FVC)均明显优于对照组,差异有统计学意义(P<0.05),血清IL-23水平显著低于对照组,差异有统计学意义(P<0.05)。与对照组比较,观察组的治疗效果明显较高,组间对比差异有统计学意义(P<0.05)。两组患者的不良反应发生率差异无统计学意义(P>0.05)。结论布地奈德与孟鲁斯特纳联合治疗支气管哮喘,临床疗效确切,且不良反应发生率不明显,有利于患者气道通气功能的恢复。
Objective To analyze the clinical efficacy and safety of budesonide combined with montelukast sodium in the treatment of bronchial asthma. Methods 96 cases of bronchial asthma patients were randomly divided into control group and observation group, 48 cases in the control group were given budesonide aerosol inhalation, 100μg / time, 2 times / d; observation group plus montelukast Oral, 10mg / time, 1 time / d. 14d for a course of treatment, continuous treatment of 2 courses, a total of 28d. Results After treatment, the airway function (FEV1, FVC, FEV1 / FVC) of the observation group was significantly better than that of the control group (P <0.05), and the level of serum IL-23 was significantly lower than that of the control group There was statistical significance (P <0.05). Compared with the control group, the treatment group was significantly higher, the difference between the two groups was statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusions Budesonide and Montelukast are effective in treating bronchial asthma. The curative effect is definite and the incidence of adverse reactions is not obvious, which is beneficial to the recovery of airway ventilation.